Global Brain (GB) has made investments in Healx (Co-Founder and CEO: Dr Tim Guilliams), a Cambridge based AI-powered and patient-inspired technology company, through its GB-VII Growth Fund Investment Limited Partnership (GB-VII).

Where the traditional drug discovery model takes more than a decade and can run into the billions of dollars, Healx’s AI-driven approach makes the process faster, more efficient, and more cost-effective.

Healx’s mission is to advance 100 rare disease treatments towards the clinic by 2025. Healnet,​ Healx’s AI platform, delivers data-driven treatment predictions, which shortens the discovery-to-clinic timeline to as little as 24 months. It is the world’s leading AI platform on rare diseases and integrates scientific literature, clinical trial results, and proprietary data in the form of a biomedical knowledge graph, pinpointing the potential therapeutic relationships between drugs and diseases. Healx’s multidisciplinary team of rare disease and drug development experts work in concert with Healnet to identify and validate the most promising treatments for a given disease.

With being impressed by Healx’s unique approaches, technologies, and strong management team and also sympathizing with its mission, GB has decided to invest in Healx. GB will leverage its resources to support Healx by assisting its penetration into the Asian market, including but not limited to building partnerships/alliances with its potential clients.

About Healx

Cambridge, U.K.
Dr Tim Guilliams

About GB-VII

GB-VII Growth Fund Investment Limited Partnership
Partner Global Brain Corporation

About GB

Tokyo, Japan
Yasuhiko Yurimoto
January, 1998